Lower MMP‐2 expression in vivo and in vitro was observed with CTPR9 pretreatment in the present study, which may have contributed to the better post‐MI contractile function but did not reduce post‐MI heart rupture. The gene discussed is MMP2; the disease is myocardial infarction.